FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Chang E, Weinstock C, Zhang L, Charlab R, et al. Clin Cancer Res 2021;27:922-927.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chang E, Weinstock C, Zhang L, Charlab R, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 2021;27:922-927.
PMID: 32962979